Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Precursor Cell Lymphoblastic Leukemia-Lymphoma

ClinicalTrials.gov lists 2,694 trials for Precursor Cell Lymphoblastic Leukemia-Lymphoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 167.

MeSH D054198 Neoplasms Neoplasm C04 C15 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 681 Phase 1/2 Phase 1/2 275 Phase 2 Phase 2 660 Phase 2/3 Phase 2/3 47 Phase 3 Phase 3 165 Phase 4 Phase 4 62 Not applicable Not applicable 371 Observational Observational 416 Phase 1 Phase 1 681 Phase 1/2 Phase 1/2 275 Phase 2 Phase 2 660 Phase 2/3 Phase 2/3 47 Phase 3 Phase 3 165 Phase 4 Phase 4 62 Not applicable Not applicable 371 Observational Observational 416

Trials per phase

2 more sections with rows

2,516 of the 2,694 trials are tagged with Precursor Cell Lymphoblastic Leukemia-Lymphoma itself; the rest are tagged with a narrower condition beneath it.

Get the Precursor Cell Lymphoblastic Leukemia-Lymphoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Precursor Cell Lymphoblastic Leukemia-Lymphoma trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 9 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 135

1990: 4 trials (Not applicable 1, Phase 2/3 1, Phase 2 2) 1991: 2 trials (Observational 1, Phase 2 1) 1992: 7 trials (Observational 2, Phase 3 1, Phase 2 3, Phase 1 1) 1993: 8 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 4) 1994: 7 trials (Phase 3 2, Phase 2 2, Phase 1 3) 1995: 18 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1/2 2, Phase 1 4) 1996: 26 trials (Observational 1, Phase 4 1, Phase 3 6, Phase 2 10, Phase 1/2 2, Phase 1 6) 1997: 41 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 7, Phase 2/3 1, Phase 2 13, Phase 1/2 2, Phase 1 13) 1998: 46 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 14, Phase 1/2 5, Phase 1 19) 1999: 66 trials (Observational 2, Not applicable 6, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 17, Phase 1/2 5, Phase 1 28) 2000: 71 trials (Observational 3, Not applicable 8, Phase 4 2, Phase 3 9, Phase 2/3 2, Phase 2 26, Phase 1/2 3, Phase 1 18) 2001: 47 trials (Observational 4, Not applicable 7, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 14, Phase 1/2 4, Phase 1 14) 2002: 68 trials (Observational 6, Not applicable 7, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 21, Phase 1/2 4, Phase 1 20) 2003: 67 trials (Observational 7, Not applicable 10, Phase 4 5, Phase 3 4, Phase 2/3 1, Phase 2 19, Phase 1/2 9, Phase 1 12) 2004: 79 trials (Observational 8, Not applicable 8, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 21, Phase 1/2 5, Phase 1 30) 2005: 82 trials (Observational 10, Not applicable 8, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 23, Phase 1/2 12, Phase 1 22) 2006: 88 trials (Observational 7, Not applicable 5, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 24, Phase 1/2 17, Phase 1 28) 2007: 96 trials (Other 1, Observational 11, Not applicable 12, Phase 4 2, Phase 3 9, Phase 2/3 1, Phase 2 22, Phase 1/2 8, Phase 1 30) 2008: 87 trials (Observational 18, Not applicable 10, Phase 4 2, Phase 3 12, Phase 2/3 3, Phase 2 14, Phase 1/2 8, Phase 1 20) 2009: 99 trials (Other 1, Observational 16, Not applicable 8, Phase 3 7, Phase 2/3 3, Phase 2 29, Phase 1/2 10, Phase 1 25) 2010: 101 trials (Observational 15, Not applicable 9, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 29, Phase 1/2 9, Phase 1 33) 2011: 76 trials (Observational 16, Not applicable 5, Phase 3 3, Phase 2/3 1, Phase 2 27, Phase 1/2 5, Phase 1 19) 2012: 73 trials (Observational 10, Not applicable 4, Phase 4 1, Phase 3 5, Phase 2 26, Phase 1/2 8, Phase 1 19) 2013: 70 trials (Observational 8, Not applicable 3, Phase 4 5, Phase 3 5, Phase 2/3 1, Phase 2 16, Phase 1/2 13, Phase 1 19) 2014: 72 trials (Observational 5, Not applicable 7, Phase 3 8, Phase 2 21, Phase 1/2 7, Phase 1 24) 2015: 62 trials (Observational 3, Not applicable 7, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 24, Phase 1/2 8, Phase 1 14) 2016: 83 trials (Observational 11, Not applicable 7, Phase 4 3, Phase 3 5, Phase 2/3 4, Phase 2 15, Phase 1/2 15, Phase 1 23) 2017: 94 trials (Observational 16, Not applicable 8, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 31, Phase 1/2 13, Phase 1 18) 2018: 81 trials (Observational 21, Not applicable 11, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 19, Phase 1/2 12, Phase 1 13) 2019: 111 trials (Observational 20, Not applicable 24, Phase 4 2, Phase 3 9, Phase 2/3 3, Phase 2 20, Phase 1/2 10, Phase 1 23) 2020: 113 trials (Observational 34, Not applicable 16, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 16, Phase 1/2 6, Phase 1 36) 2021: 113 trials (Observational 30, Not applicable 23, Phase 4 5, Phase 3 4, Phase 2/3 2, Phase 2 19, Phase 1/2 12, Phase 1 18) 2022: 134 trials (Observational 30, Not applicable 33, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 18, Phase 1/2 11, Phase 1 35) 2023: 128 trials (Observational 39, Not applicable 30, Phase 4 4, Phase 3 4, Phase 2/3 1, Phase 2 15, Phase 1/2 12, Phase 1 23) 2024: 135 trials (Observational 27, Not applicable 28, Phase 4 4, Phase 3 2, Phase 2/3 1, Phase 2 33, Phase 1/2 17, Phase 1 23) 2025: 103 trials (Observational 13, Not applicable 26, Phase 4 1, Phase 3 3, Phase 2/3 6, Phase 2 25, Phase 1/2 11, Phase 1 18)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 97
2025 103
2024 135
2023 128
2022 134
2021 113
2020 113
2019 111
2018 81
2017 94

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 110 trials starting in 2026 and about 110 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 290 trials still running at the 2026-10-09 snapshot; registered median of 43 months across 1,680 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 681
Phase 1/2 275
Phase 2 660
Phase 2/3 47
Phase 3 165
Phase 4 62
Not applicable 371
Observational 416
Expanded access 16
Unknown 1

How many Precursor Cell Lymphoblastic Leukemia-Lymphoma trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 74
Recruiting 353
Enrolling by invitation 13
Active, not recruiting 151
Available 6

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Precursor Cell Lymphoblastic Leukemia-Lymphoma trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 167
Children's Oncology Group 75
Novartis Pharmaceuticals 32

Which drugs are being tested for Precursor Cell Lymphoblastic Leukemia-Lymphoma? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 416
Busulfan 112
MERCAPTOPURINE 107

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 262
HD- Methotrexate (MTX) 236
Cytarabine IT 222
Vincristina 192
Dexamethasone/Dexamethasone acetate 169

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Precursor Cell Lymphoblastic Leukemia-Lymphoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 2,032 156
Neutrophil count decreased 1,694 60
Platelet count decreased 1,536 67
Sepsis 908 167
White blood cell decreased 795 27

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Precursor Cell Lymphoblastic Leukemia-Lymphoma? (1,415)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS. Clinical pharmacology and therapeutics 2026 Yes
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia. Blood advances 2026 Yes
Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations. American journal of hematology 2026 Yes
Early Toxicity in Childhood Acute Lymphoblastic Leukemia: A Comparison of NOPHO ALL2008 and ALLTogether Protocols in Sweden. Pediatric blood & cancer 2026 Yes
Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With Asparaginase. Clinical pharmacology and therapeutics 2025 Yes

Showing 5 of 1,415 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (10)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Acute lymphoblastic leukemia Lifetime prevalence 1-5 / 10 000 United States US Exact
Acute lymphoblastic leukemia Annual incidence 1-9 / 100 000 United States US Exact
Acute lymphoblastic leukemia Annual incidence 1-9 / 100 000 United States US Exact
Acute lymphoblastic leukemia Lifetime prevalence 1-5 / 10 000 United States US Exact
Acute lymphoblastic leukemia Point prevalence 1-5 / 10 000 Europe Not stated Exact

Showing 5 of 10 prevalence observations.

Start your 14-day trial Email me all 10 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Acute lymphoblastic leukemia 513 Exact Orphadata Science knowledge files, Product 1
Acute lymphoblastic leukemia 513 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages